➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Medtronic
Express Scripts
Colorcon
McKinsey

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

TARGRETIN Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Targretin, and when can generic versions of Targretin launch?

Targretin is a drug marketed by Valeant Luxembourg and Bausch and is included in two NDAs.

The generic ingredient in TARGRETIN is bexarotene. There are seven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the bexarotene profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Targretin

A generic version of TARGRETIN was approved as bexarotene by BIONPHARMA INC on August 12th, 2014.

  Try Before You Buy

Drug patent expirations by year for TARGRETIN
Drug Prices for TARGRETIN

See drug prices for TARGRETIN

Recent Clinical Trials for TARGRETIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Centre, SingaporePhase 1
National Medical Research Council (NMRC), SingaporePhase 1
Georgetown UniversityPhase 1

See all TARGRETIN clinical trials

Pharmacology for TARGRETIN
Drug ClassRetinoid

US Patents and Regulatory Information for TARGRETIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999 AB RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
Bausch TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TARGRETIN

Supplementary Protection Certificates for TARGRETIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0637297 C300054 Netherlands   Try Before You Buy PRODUCT NAME: BEXAROTENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET EEN HYDROXYVER- BINDING MET DE FORMULE R9OH, WAARIN R9 EEN; NAT. REGISTRATION NO/DATE: EU/1/01/178/001 20010329; FIRST REGISTRATION: EU/1/01/178/001 20010329
0637297 CA 2001 00032 Denmark   Try Before You Buy
0637297 SPC/GB01/041 United Kingdom   Try Before You Buy SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
0637297 SPC013/2001 Ireland   Try Before You Buy SPC013/2001: 20031205, EXPIRES: 20160328
0637297 01C0027 France   Try Before You Buy PRODUCT NAME: BEXAROTENE; REGISTRATION NO/DATE: EU/1/01/178/001 20010329
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKesson
Dow
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.